Art of Boring

Episode explores the GLP-1 supply chain, highlighting massive API demand growth and purification bottlenecks.

23 min Listen to the original Episode page
GLP-1BiotechSupply ChainPharmaceuticalsCDMOSpecialty Chemicals

Summary

Joshua Samuel discusses the emergence of 'consumer biotech' driven by GLP-1 drugs reaching 44 million users within five years. He explains how the shift from injectables to oral pills could require 2-10x more active pharmaceutical ingredient (API) due to low bioavailability. The episode highlights that peptide synthesis yields compound over many steps, making process engineering critical. Samuel identifies a purification bottleneck involving silica gel, where one supplier holds ~70% global market share. He argues that drug approvals lock in suppliers, creating durable revenue streams for consumable providers despite their classification as specialty chemical companies.

Key takeaways

  1. 1
    Recently, Sandos, which is a Swiss generic manufacturer, in their capital markets, they were estimating that this could increase the size of the market by another two to seven times over the next, I think, five to ten years.

    Unidentified speaker (speaker_2) · 5:36

Episode sections

  1. 0:00 – 1:17

    Introduction: GLP-1s Beyond the AI Trade

    Host introduces guest Joshua Samuel to discuss the peptide supply chain behind GLP-1 obesity treatments, highlighting the unglamorous but critical manufacturing suppliers beneath the innovators.

  2. 1:17 – 2:49

    Consumer Biotech: 44 Million GLP-1 Users in Five Years

    Samuel notes that GLP-1 drugs have reached 44 million users within five years of Ozempic's launch, outpacing traditional small-molecule and biologic blockbusters and creating a new 'consumer biotech' asset class.

  3. 2:49 – 5:01

    Small Molecules, Biologics, and Peptides Explained

    The speakers define small molecules (chemical synthesis, <1000 Daltons), biologics (fermentation, >10,000 Daltons), and peptides (intermediate size), noting that peptide demand has shifted from niche kilograms to industrial tons.

  4. 5:01 – 6:48

    GLP-1 Generics, Oral Pills, and Patent Expiry

    Samuel argues that patent expiries and the entry of generics like Sandoz could expand the total addressable market by 2-7x, while the shift to oral pills adds another layer of volume growth.

  5. 6:48 – 8:28

    Why Oral GLP-1 Pills Need More API

    Oral delivery suffers from low bioavailability (<1% vs >90% for injections), requiring 2-10x more active pharmaceutical ingredient (API) per dose compared to injectables, depending on the manufacturer's technology.

  6. 8:28 – 10:56

    How Peptides Are Made: The LEGO Analogy

    Peptide synthesis is compared to building a LEGO set, where amino acids are added sequentially to a resin base; multi-step processes make yield management critical, similar to semiconductor manufacturing.

  7. 10:56 – 12:29

    The Purification Bottleneck and Silica Gel

    Purification using silica gel is a mission-critical bottleneck; one supplier holds ~70% global market share and generates ~40% of its profits from this healthcare-related consumable, despite screening as a specialty chemical company.

  8. 12:29 – 22:33

    Why Drug Approvals Lock In Suppliers

    Once a drug passes Phase 2 trials, manufacturers are effectively locked into their consumable suppliers because changing vendors requires costly and time-consuming regulatory re-approval.

Assets discussed

AssetKindStanceContext
ELI LILLY & CoLLYequityneutralEli Lilly's stock price has been on tear for several years.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

GLP-1 drugs have ramped to 44 million users within five years of Ozempic's launch.

Unidentified speaker (UNKNOWN) ·1:11

How to verify: Check Eli Lilly and Novo Nordisk quarterly earnings reports or press releases for patient volume data between 2026 and 2026. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Primary source

Small molecules weigh less than 1,000 Daltons; biologics weigh over 10,000 Daltons.

Unidentified speaker (speaker_2) ·3:20

How to verify: Verify against standard pharmacological definitions of molecular weight for small molecule drugs and biologics in FDA guidance documents. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Sandoz estimates the GLP-1 market could increase 2-7 times over the next 5-10 years due to generics.

Unidentified speaker (speaker_2) ·5:36

How to verify: Locate Sandoz's capital markets presentation or investor day materials from the period referenced (late 2026) to confirm the TAM expansion estimate. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Primary source

Oral GLP-1 pills have bioavailability of less than 1% without advanced chemistry, compared to >90% for injections.

Unidentified speaker (speaker_2) ·7:19

How to verify: Review clinical pharmacology data for oral GLP-1 formulations (e.g., from Novo Nordisk or Eli Lilly) in FDA briefing documents or peer-reviewed journals. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Primary source

Oral pills require 2-4x more API for innovators like Novo Nordisk, and 8-10x for others.

Unidentified speaker (speaker_2) ·7:59

How to verify: Compare API dosage per dose between injectable and oral versions of GLP-1 drugs in prescribing information or clinical trial results. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Primary source

One silica gel supplier has ~70% global market share and generates ~40% of profits from healthcare consumables.

Unidentified speaker (speaker_2) ·11:25

How to verify: Identify the company via its investor relations page or annual report (likely a specialty chemicals firm) and verify market share data from industry reports (e.g., ChemAnalyst, ICIS) and profit breakdowns from financial filings. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Primary source

Pharmaceutical consumable companies in the US trade at ~25x earnings; the silica gel supplier trades at 16-17x.

Unidentified speaker (speaker_2) ·18:32

How to verify: Calculate the P/E ratio of the specific silica gel company from its stock price and trailing twelve months earnings, and compare to an index of US healthcare consumable companies. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

70% of small molecules under development are moderate to highly complex (4-12+ steps).

Unidentified speaker (UNKNOWN) ·20:49

How to verify: Review industry reports on small molecule drug discovery pipelines (e.g., from BioPhorum or FDA databases) to assess the complexity of current development candidates. For recent events, verify 2026-08-05 through 2026-11-05. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the 44 million user claim by checking Novo Nordisk and Eli Lilly quarterly earnings reports or FDA approval databases.
  • Confirm Sandoz's market expansion estimates by reviewing their investor presentations or third-party market research from IQVIA or EvaluatePharma.
  • Check the specific bioavailability data for oral GLP-1 formulations from primary clinical trial publications or company technical whitepapers.
  • Identify the 'specialty chemicals company' with 70% silica gel share by searching for major silica gel manufacturers and their segment revenue disclosures in 10-K filings.
  • Review the regulatory re-approval requirements for changing CDMO suppliers by consulting FDA guidance on post-approval changes to drug substances.
  • Analyze the valuation multiples of identified silica gel suppliers against peers to assess if the 'healthcare vs. chemical' classification is accurate.
  • Look for counter-arguments regarding oral pill bioavailability improvements that might reduce the 2-10x API multiplier.
  • Check for any recent patent expiries or generic approvals for GLP-1 drugs that might alter the market size projections.
Full transcriptexpand
0:00
Unidentified speaker (speaker_0): Coming up on the art of boring, with all eyes on AI, what are some of the other areas seeing transformational changes in demand? Equity analyst Josh Samuel joins me from Singapore to dig into peptides, the drug class behind the blockbuster obesity treatments that you've all heard of, and the often unglamorous suppliers in the manufacturing chain underneath them. Along
0:20
Unidentified speaker (speaker_0): the way, a Lego analogy, some similarities with semiconductors, and a fair degree of chemistry, the chemistry of peptides. that is, not the chemistry between me and Josh.
0:33
Unidentified speaker (speaker_1): This podcast is for informational purposes only. Information relating to investment approaches or individual investments should not be construed as advice or endorsement. Any views expressed in this podcast are based upon the information available at the time and are subject to change.
0:49
Unidentified speaker (UNKNOWN): Welcome
0:50
Unidentified speaker (speaker_0): back to the podcast.
0:51
Unidentified speaker (speaker_2): You're up. Good to see you again and good morning.
0:55
Unidentified speaker (UNKNOWN): Thanks
0:56
Unidentified speaker (speaker_0): for staying up late. Late in the day for you out in Singapore. I was looking back. I think it's been about two years since we last spoke about GLP ones on the art of boring. I know you've been spending time in the space. Can you give us a sense of why you're spending time there and what's been happening?
1:11
Unidentified speaker (UNKNOWN): To
1:11
Unidentified speaker (speaker_2): make a long story short, shot, the growth of GLP1s. has been exceptional. There's basically been no drug class like this. GRP1s since Ozampic was launched has ramped to 44 million users within five years. And just for context, if you compare that versus say the top three blockbuster
1:31
Unidentified speaker (speaker_2): drugs in small molecule, small molecule is a class of drugs that's similar to Panadol and the tablets that you take, and large molecule with which has been biologics or the more popular drug over the past maybe 20 years. GLP1 has basically ramped in a way that is beyond the blockbusters of any of these other drug classes. That's what
1:51
Unidentified speaker (speaker_2): got some of the interest. But then the other part of it was understanding that hey, you could say it's a different kind of molecule in itself with its own value chain. And so with that comes sort of opportunity. in taking down the value chain because there's effectively, you could say a new asset class being created within the pharmaceutical land. You put the numbers aside,
2:11
Unidentified speaker (speaker_2): I think at a high level, what's interesting for me, and I heard this at the conference just a few weeks ago in Europe, you can think of GLP ones or peptides, I'm going to use them interchangeably, as being what they call consumer biotech. So previously, drugs, you you're taking it for an illness or something like that, GRP once came about to
2:31
Unidentified speaker (speaker_2): treat diabetic patients. But I think what's happened is that it's become a bit more than that. It's become mass market. And so hence the name consumer biotech. And that's kind of the reason why there hasn't been anything like this in the pharmaceutical land. It is pharmaceuticals, but it's going beyond that to something that's available to the masses.
2:48
Unidentified speaker (speaker_0): You mentioned a couple of terms that I'm just wondering. if you can better explain for listeners and for me.
2:55
Unidentified speaker (speaker_0): Small molecules, biologics, and then this new class of peptides. What's different about them?
3:00
Unidentified speaker (speaker_2): Small molecules, think of them as drug products that are synthesized from chemicals. So effectively, small molecules is what's been around for, I will say, over 100 a hundred years. I will use the example of Penodol Panotol once again, because at least in Asia. it's very popular. You take it when you have a fever. It's synthesized basically from chemicals and you could trace its
3:20
Unidentified speaker (speaker_2): roots back to petrochemicals effectively. In scientific terms, it's stuff that weighs less than a thousand Deltons. That's just how you put a molecular weight on these products. And then there's large molecules, which has been, I think, the area of focus in the investing world over the past maybe twenty 20 years. They're also called
3:39
Unidentified speaker (speaker_2): biologics. And these are much larger molecules which weigh over 10,000 deltons. To create a small molecule, use chemical synthesis, but to create a large molecule, you have used typically a fermentation kind of process. I'm not a doctor or PhD scientist, just a business school guy. But in my simple elementums, one is done with chemical synthesis, one is
3:59
Unidentified speaker (speaker_2): done with fermentation, and they are really different classes. of size. So one is much bigger than the other. And peptides sit in between. Up to the point of GLP1, peptides was a ridiculously small market. If you, as a pharmaceutical innovator, place an order for let's call it like 100 kg of peptide API. So
4:19
Unidentified speaker (speaker_2): API active pharmaceutical ingredient, or in simple terms, think of it as the drug substance, the stuff that makes your drugs. You order ordered 100 kg of it.
4:27
Unidentified speaker (speaker_2): let's call it, you know, maybe five to seven years ago. The CDMOs, which is a contract development manufacturing and outsourcing, or you could think of them as the Foxcorn or the contract manufacturers that supply the pharmaceutical guys. Those guys will be popping champagne because that would be considered a super large order, probably put you in the top 10 ten globally for the year. You're done
4:47
Unidentified speaker (speaker_2): for the year. But that's because it was a niche asset class. What's really interesting is that with GLP one and this whole class of drugs that has grown, people are not ordering in the tons. There's been a huge step change that's going on in the industry.
5:01
Unidentified speaker (UNKNOWN): So
5:01
Unidentified speaker (speaker_0): you've seen a massive jump in demand for these peptides, GLP1s being one of them, of course, the major use case being targeting weight loss. Isn't this behind us though? Eli Lilly's stock price has been on tear for several years. Why are you looking at this now?
5:16
Unidentified speaker (speaker_2): The first layer that benefited from this was the innovators. Eli Lilly and Nova Norris, or also Nova Norris stock price hasn't been great for a variety of factors, execution related, etc. But then I think what's interesting now is that some of these drugs are going off patent. And that's actually really interesting to us because I think from the innovator side, yeah,
5:36
Unidentified speaker (speaker_2): pricing is as good as it gets, but when these drugs go off patent, we're talking about a further increase in the TAM or the addressable market. Recently, Sandos, which is a Swiss generic manufacturer, in their capital markets, they were estimating that this could increase the size of the market by another two to seven times over the
5:56
Unidentified speaker (speaker_2): next, I think, five to ten years. I think from a volume perspective, we are still early days, and that's just one part of it. The second part is the introduction of oral peptides. And I'm sure we'll go into this later in the conversation. But so far most of these drugs, or let's call it like 90 plus percent of these drugs, are being delivered through subcutaneous injections. What's being pushed now
6:16
Unidentified speaker (speaker_2): into the market is oral pills. The market is still expanding through delivery mechanisms too.
6:21
Unidentified speaker (UNKNOWN): When
6:21
Unidentified speaker (speaker_2): you combine these factors, I think it's quite an interesting setup where you have generics entering the market, you have uh oral pills. which are also coming in. What excites me is the value chain that sits underneath the innovators. We can talk about the C DMOs, we can talk about the consumables that are used to manufacture peptides, but with volume growth, there's gonna be a lot of
6:41
Unidentified speaker (speaker_2): beneficiaries and the inflection point where some of these companies are starting to become big enough in enter our investable universe.
6:48
Unidentified speaker (UNKNOWN): Can
6:48
Unidentified speaker (speaker_0): you talk just a little bit more on the oral side? It's my understanding that you mentioned APIs before. These drugs delivered orally required like a step function more in terms of APIs.
6:59
Unidentified speaker (speaker_2): Just for understanding, a peptide comprises of amino acids. Trizepatite, which is the popular one by Eli Lili, is a 39-chain amino acid. Amino acid is something like protein. So your body tries to digest it, you ingest it as a pill. And so that's why most of these drugs are being delivered subcutaneously, it bypasses your stomach.
7:19
Unidentified speaker (speaker_2): So they call it bioavailability. The bioavailability when you're going through an injection is over 90%. If you were to take it as a pill, your body's gonna try to eat it. And so the bioavailability, if you don't do any funky chemistry work, is it's probably down to less than 1%. So in theory, you
7:39
Unidentified speaker (speaker_2): go from something that's 95% efficiency to now less than 1%. You should, in theory, need 95 times more drug substance or API going from an injection to an oral pill. Of course, companies like Nova Knowledge have been innovating here. And more realistically, with a bunch of other technology, they're able to get it
7:59
Unidentified speaker (speaker_2): down to something like a two to four times increase in the amount of API. if you're an overnordist. But if you're not novel novelist, you're probably talking somewhere in the range of eight to ten times based on our conversations with some of the contract manufacturers. Nevertheless, you're still talking about a step change in the amount of drug substance required. And why this is important
8:18
Unidentified speaker (speaker_2): is because it's the same. Whether it's Is an injection or an oral pill, the API is the API. It's the same product that you have to buy from. a contract manufacturer.
8:28
Unidentified speaker (speaker_0): Okay, there's been this explosion in demand that may benefit the innovators. However, they're coming off patent, whether it's two to four times or more than that, the explosion is going to benefit those who are further down the value chain. Can you take a moment just to explain how peptides are actually made? I think that'll give us some insight into where those bottlenecks might be.
8:47
Unidentified speaker (speaker_2): The way you manufacture a peptide is very different from biologics and also quite different from small molecules. So remember I said tranzepatite, which is Eli Lili's flagship product at the moment. It's a 39-chain peptide, meaning there's 39 different kinds of amino acids that are linked together. Think of it as a Lego block. You first have the
9:06
Unidentified speaker (speaker_2): base plate, which is a resin. Just for simplicity's sake, there's two ways of doing it. There's fermentation, which Nova Knowledge uses, but I'm talking about Eli Lili here. and they've chosen to use chemical synthesis. So you start with a base page, which is the resin, and you assemble the Lego block piece by piece. And when I say piece by piece, it's 39 different pieces. And you put in the first
9:26
Unidentified speaker (speaker_2): amino acid, you flush it up with solvents, you put the second one, and so you assemble a block. Now there's been innovation here and what white Eli LID Lili leaders does is that they do it in fragments, so maybe there are concurrently three different fragments or four different fragments. that are being built, and then they combine the fragments together. But long story short, it's still Lego. There's a bit of a TSMC story here. We've
9:46
Unidentified speaker (speaker_2): invested in semiconductors, and one thing we've learned is that when you have a multiple step process, the yield starts to become very important. You're talking about 39 different steps. Having a 99% yield in each step, it starts to compound the errors over time. So and end yield will actually be much. lower. And so the process manufacturing know-how
10:06
Unidentified speaker (speaker_2): becomes very important, which is why we've invested in some C DMOs, because process engineering is key, execution is key, and these guys are able to figure out the yield side of things very well. So starting with the resins, you build the Lego block. And once you're done with it, you have to then purify it because we need the exact 39-chain peptide to be the stuff that is going to your
10:26
Unidentified speaker (speaker_2): bloodstream. You can't have the 38-chain or the 37-chain peptide or the 40-chain peptide. The final process is actually called purification, where you use a different kind of resin and this is called silica gel. It's very interesting because you need the precise type of silica gel to ensure that the silica gel is more or less the perfect fit
10:46
Unidentified speaker (speaker_2): for that kind of peptide and it sticks to the silical gel, whereas every other impurity gets washed. off. That's kind of the manufacturing process behind peptide production.
10:56
Unidentified speaker (speaker_0): Through that chain, Josh, where are the biggest bottlenecks? For my seat, I have no idea what seems easy, what seems hard. What are the key parts in that chain?
11:05
Unidentified speaker (speaker_2): I'm just gonna focus on the parts that we think are most investable. And so the final step, which is purification, is one that you can't really escape. If you're doing fermentation, which is like what Nova Norris is doing, or if you're doing chemical synthesis, you have to still purify your product at the end of the day. We've actually found out there is one company that has about
11:25
Unidentified speaker (speaker_2): 70% market share globally for this tech. It was quite a discovery for us because it's a specialty chemicals business. It doesn't screen up as a healthcare company, but when we came across it, do the typical screening, you will say, Oh it's only like 15% or something like that of its sales, which is the healthcare. But this business is so profitable that it's
11:45
Unidentified speaker (speaker_2): generating almost 40% of its profits at the moment. That's the areas of the value chain that we like where there's companies with a moat that dominate a mission critical pinch point in the value chain. Why is it mission critical? Because remember, yields are very important. So I'm probably exaggerating it by saying it's the same as TSMT. It is
12:02
Unidentified speaker (UNKNOWN): not.
12:02
Unidentified speaker (speaker_2): It's much simpler than that. But you want to make sure you get the highest yield from every step. And so there's purification that is used in multiple steps. When you're doing the fragments, you need to purify that too. But you also need to purify to make sure you get that right drug substance. And it's the same media that is used for these purification steps, be it in the front end or back end. If you choose a suboptimal type of acidical silicon gel, you
12:22
Unidentified speaker (speaker_2): get a lower yield. That will affect your cogs, it will affect your whole ROI. of your manufacturing setup.
12:29
Unidentified speaker (speaker_0): There's one other thing specific to healthcare, I believe, that may be different than semiconductors. Can you talk about how drug approvals actually encapsulate the manufacturing process too?
12:40
Unidentified speaker (speaker_2): First you have the preclinical work. Once you get an approval to test the drug, it goes through phase one, phase two trials, and phase three trials. These are multi-year processes. Typically once you're you are past phase two, whatever vendors you are using, be it on equipment or consumables like the silica gel, you're more or less locked in. If you were to change it or
13:00
Unidentified speaker (speaker_2): try to change the manufacturing process, you would basically have to go and file for approval, redo the test. It's just expensive and time consuming. You don't want to do that because at least more for the innovator side of things, time to market is of the essence.
13:14
Unidentified speaker (UNKNOWN): You
13:14
Unidentified speaker (speaker_2): wanna be first to market. The longer time you take to go to market, you're gonna have a shorter patent protected period or exclusivity period. Typically, once your consumable is locked in in phase three, it's very difficult to switch. It's just not worth the administrative hassle of you're gonna save a few hundred thousand dollars, but then you're gonna have to
13:34
Unidentified speaker (speaker_2): pay maybe a million bucks somewhere else. It's not worth it in the grand scheme of things.
13:38
Unidentified speaker (UNKNOWN): Can
13:38
Unidentified speaker (speaker_0): I stick with your semiconductor analogy? A huge explosion in demand with bottlenecks potentially in the manufacturing side of things and with specific companies owning really key parts of that manufacturing process in extremely niche aspects, whether it's silica gels or others. What else is the same or what else is
13:58
Unidentified speaker (speaker_0): different about that comparison between those two sectors?
14:01
Unidentified speaker (speaker_2): Outside of the AI trade mode. which you know is very popular, there's still other parts of the market that are growing. And I think what I want to say is that this is an area where there's actually still very decent growth. I was looking at a Bernstein report. They were talking about a 9x increase in API demand associated with peptides. Most people would guess it's that semiconductors. No, it's not, it's actually peptides. So
14:21
Unidentified speaker (speaker_2): the growth potential is somewhat similar as a high growth market, and it's driven by multiple. factors. Like what we discussed, the introduction of oral peptides, which is additive to the market. As part of the due diligence, I actually went to go and see an endocrinologist just for fun. And you know, I understand why I should take peptides and stuff like that. He was explaining to me how the oral pills are
14:41
Unidentified speaker (speaker_2): actually meant for different types of patients than the injectables. The injectables are probably, you could say, the more serious cases, or it's as meant for obesity, people. who have heart conditions. And then on the fringes, oral pill could make more sense for people who have perhaps less pre-existing conditions or less serious weight loss targets that you
15:01
Unidentified speaker (speaker_2): need to hit. It's kind of additive rather than injection versus oral. And that's what's happening in the market right now. The injections are still growing, but oral is also still growing at the same time. That's one interesting angle is that you have multiple idiosyncratic growth options that. are driving this sector. Like what we mentioned, there's the oral pill, there is the generics that are coming in.
15:21
Unidentified speaker (speaker_2): Those are quite big forces behind it. And then not to mention, there's still innovation that's going on. So the game is not over for Elaine Lilly and Nova and all this. So what's going off patent is what we call single angonists. Anganus. These drugs are trying to target a particular hormone receptor. So when you say a GL. GLP1, it's targeting like a GLP1
15:41
Unidentified speaker (speaker_2): receptor. And so that was the original stuff that we are all talking about. But what Eli Lili and Nova Nordists are doing is that they're now having dual angonis
15:49
Unidentified speaker (UNKNOWN): and
15:49
Unidentified speaker (speaker_2): triple angonis. So transepatite targets two receptors, GLP and GIP, if I'm correct. Triple receptor peptides, which are You're targeting three. And why are people doing that? It's because it's more effective. So you get better weight loss. with less side effects, for example. So we're talking about can you lose weight without losing muscle mass? And we're talking
16:09
Unidentified speaker (speaker_2): about surgical level weight loss here. So it's kind of the holy grail, right? It's like hey, don't have to go through surgery, don't look ripped after this, and without going to the gym, it's like it's almost a miracle, right? So but you can see there is still innovation going on, and that's also an important part. And the growth we've seen so far has just been dragged. driven by innovators, and that's what really excites me. So it's like
16:29
Unidentified speaker (speaker_2): base case that hey, this thing is still growing through innovation, and then you have that 2 to 7x potential tab increase from generics, kind of for opening up the single angonist market. It's very interesting to see so many multiple growth options. The final piece on growth I would say is Nova Noddish. So they are really betting heavily on oral peptides. In fact, in the
16:49
Unidentified speaker (speaker_2): capital markets, they day, I think a few weeks ago, they mentioned they're gonna 10x their oral peptide capacity. I did the math on that. The 10x in oral peptide capacity, if you assume that 2 to 4x step up in API between oral versus injectable, is equivalent to the entire market right now, just coming from one
17:09
Unidentified speaker (speaker_2): company. So anyone who's doing the silica gel or some of these other consumables, that you can see how there's more. multiple ways to make money. You don't need all the stars to align, just some of them aligning would already be enough to decently grow the market.
17:21
Unidentified speaker (UNKNOWN): Okay,
17:21
Unidentified speaker (speaker_0): so high growth. Does that come with high valuations too?
17:25
Unidentified speaker (speaker_2): So we first started investing in this sector in the start of this year, and it wasn't on the consumable side, it was actually on the CDMO CMO side, and we were getting reasonable valuations, we're getting IRRs in the low double. double-digit range. And I think that's partially thanks to the whole AI trade because the AI trade has been taking a
17:45
Unidentified speaker (speaker_2): lot of attention and focus away from other sectors. And so earlier on the start of the years, when we first kind of identify, hey, there could be an opportunity here where people are not really pricing in some of these growth options. Unfortunately, I would say on the C DMO side of things, what has happened is AI drug discovery has become the new buzzword. There's been some high hype around that, which has meant
18:05
Unidentified speaker (speaker_2): valuations can be quite volatile, right? Because people start to, is this gonna be an AI bottleneck? It's like, oh no, not again, but yeah.
18:12
Unidentified speaker (UNKNOWN): But
18:12
Unidentified speaker (speaker_2): on the consumer side, no, I would say that some of the companies we've bought silica gel, 70% market share, that was trading at like 16, 17 times earnings. The market's not dumb. So like there's risk. Like the rest of the business is causing caustic soda. manufacturing, which is very sensitive to energy prices. And so you can imagine what's going on
18:32
Unidentified speaker (speaker_2): in the world right now, the Middle East, oil prices. That's not great for the business. But I think this is the beauty of our philosophy: that we're thinking out three years, five years, this peptide business is going to grow.
18:44
Unidentified speaker (UNKNOWN): For
18:44
Unidentified speaker (speaker_2): all these numbers, I'll show you. I don't be precisely wrong, but there are multiple ways where the market grows multiple times. 20-30% growth rate sustained over a three to five year horizon isn't too extreme for some of these businesses. And you consider that, hey, this business has 40% of its operating profit already from a silica
19:04
Unidentified speaker (speaker_2): gel that is used for peptide manufacturing. Three years from now, four years from now, this business is going to look more like a healthcare company than uh a speciality specialty chemical business. And pharmaceutical. consumable companies in the US trade at like 25 times eBay in developed markets, and this business is trading nowhere near that. So it's one of the situations where you're paid
19:24
Unidentified speaker (speaker_2): to wait and the market wasn't pricing in. It's not treating the stock like a healthcare stock, a high growth stock. It's just treating it like a specialty chemical stock.
19:32
Unidentified speaker (speaker_0): We've spent most of this conversation focused on a very, very specific part of the healthcare arena. the value chain with peptide manufacturing. But you mentioned you were just at a healthcare conference. And Josh, to close here, I just wonder, can you step back a bit? What are some of the other bigger trends in the healthcare space that you think are worth
19:52
Unidentified speaker (speaker_0): paying attention to?
19:53
Unidentified speaker (UNKNOWN): The
19:53
Unidentified speaker (speaker_2): most cliche one is going to be AI drug discovery, but I would say that's actually not the thing that interests me the most. I think there's so many other trends beyond that that is There changes in regular regulation that will mean there's winners and losers in some cases. The simple one is what are the implications of the changes in regulation
20:13
Unidentified speaker (speaker_2): for analytical software? Because what's happening globally is that it's becoming easier to launch a biosimilar. So, biosimular is the generic for a large molecule. And previously you needed to do phase three trials, and that's kind of been curtailed. But to replace that, there's more analytical work. We already own one of the
20:32
Unidentified speaker (speaker_2): companies that is playing a mission critical role, helping with the increased regulatory analytical workload that comes along with the changes in regulation. The other interesting insight was around how Now, small molecule drug discovery is at an inflection point.
20:49
Unidentified speaker (UNKNOWN): So
20:49
Unidentified speaker (speaker_2): remember we talked about small molecules. being around for over 100 years, and typically it's like a two, three-step process. One interesting learning was that actually close to 70% of small molecules that are under development at the moment, uh, you could say moderate complexity or highly complex. So we're talking about four to
21:09
Unidentified speaker (speaker_2): seven steps for moderate and highly complex being more than 12 twelve steps. So there is a change in the value chain that's going on and that's going to be the icing on the cake. There's implications for this of course and we are in the process of initiating on companies that actually benefit from this step change. Many insights coming out of the pharmaceutical space is always great to be on the ground.
21:29
Unidentified speaker (UNKNOWN): At
21:29
Unidentified speaker (speaker_2): seventy-five meetings over seven working days at two different conferences. So attending panels, talking to people at booths, asking questions, but that's kind of the beauty of AI is that it's enabled me to spend more time on the ground. And then you get these insights connecting the dots, going with the people and talking to them and coming back and connecting the dots and
21:49
Unidentified speaker (speaker_2): finding great insights for our clients and our portfolio.
21:53
Unidentified speaker (speaker_0): Hopefully one of the other benefits from AI with this extra time is more time for you to join us and share with listeners some of your insights. We'd Would love to have you back in the coming months to talk a bit more about some of those other themes.
22:03
Unidentified speaker (speaker_2): I'm looking forward to that, Rob.
22:05
Unidentified speaker (speaker_0): Likewise. Thanks, Josh. Have a great night.
22:07
Unidentified speaker (speaker_2): Thank you.
22:09
Unidentified speaker (UNKNOWN): Hi,
22:09
Unidentified speaker (speaker_0): everyone. Rob here again. To subscribe to the Art of Boring podcast, go to more.com. That's M-A-W-E-R.com forward slash podcast or wherever you download your podcasts. If you enjoyed this episode, please leave a review on iTunes, which will help more people discover the be boring make money philosophy.
22:27
Unidentified speaker (speaker_2): Thanks for listening.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Art of Boring

Art of Boring

AI Build-Out: What We Know, What We Don't, and What's in the Stock | EP 236

Episode discussion: Petkovic discusses AI supply constraints, enterprise adoption, and political risks in data center build-out

Speakers’ claims: Irena Petkovic joins the Art of Boring podcast to analyze the current state of the AI build-out following recent market volatility. She argues that hyperscaler growth is now bottlenecked by data center construction speed rather than demand, citing revenue acceleration from Amazon AWS and Google Cloud. Petkovic highlights significant enterprise adoption data from Anthropic's S-1, noting that Fortune 500 spending on AI remains a tiny fraction of total expenses. The discussion also covers the increasing reliance on external financing for infrastructure, potential political headwinds in key states, and the structural shift in internet traffic caused by AI agents bypassing traditional ad models.

Artificial IntelligenceData CentersCloud Computing
19 min4 assets10 claims to verify
Art of Boring

Global Small Cap: A New Lead Manager on the Missing Premium, Local Businesses, and Talent Density | EP 235

Episode discussion: Ching Chang on Small Cap Premium Disappearance and Local Business Opportunities

Speakers’ claims: Ching Chang discusses his evolution from value investing to focusing on quality compounding companies, citing his experience at Ontario Teachers' Pension Plan. He attributes the disappearance of the small cap premium to companies staying private longer and large-cap tech firms scaling without capital constraints. Chang views small caps as diversifiers with local business focus rather than expecting a return of the historical premium. He emphasizes the need for regional overlays to manage macro risks and evaluates management teams based on customer focus and talent density.

Small-cap investingPrivate equityChina markets
26 min2 assets8 claims to verify
All insights